Literature DB >> 1871050

The preparation and evaluation of a tablet dosage form of cyclosporine in dogs.

H Y Abdallah1, M Mayersohn.   

Abstract

Cyclosporine (CsA) is commercially available for oral administration as a solution in olive oil with alcohol and an emulsifier. To improve its variable absorption and low patient acceptability, several oral formulations were prepared and tested in vitro and in vivo in dogs. A tablet formulation prepared by direct compression was then selected for comparison with the commercial oil solution placed into soft gelatin capsules. The study involved a randomized crossover design in six dogs. In order to determine absolute bioavailability and to compensate for any time-dependent changes in clearance, an intravenous tracer dose of 3H-CsA was administered along with each oral test product on each of two occasions. Absolute bioavailability (mean +/- SD) was 46.0 +/- 11.1 and 45.4 +/- 9.9% for the capsules and tablets, respectively. Cmax, tmax, and mean absorption time were not significantly different between the two products. No differences were observed in the pharmacokinetics of the intravenously administered CsA in the two experiments, which were separated by 8-13 days. We conclude that the proposed tablet formulation for CsA is equivalent in dogs to the commercial dosage form placed into soft gelatin capsules.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1871050     DOI: 10.1023/a:1015815614959

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  9 in total

1.  Cyclosporine Monitoring and Pharmacokinetics in Pediatrie Liver Transplant Patients.

Authors:  G Burckart; T Starzl; L Williams; A Sanghvi; C Gartner; R Venkataramanan; B Zitelli; J Malatack; A Urbach; W Diven; R Ptachcinski; B Shaw; S Iwatsuki
Journal:  Transplant Proc       Date:  1985-02       Impact factor: 1.066

2.  Area-based estimation of the initial volume of distribution and elimination rate constant following intravenous bolus injection.

Authors:  S P Khor; S L Johnson; M Mayersohn
Journal:  J Pharm Sci       Date:  1991-11       Impact factor: 3.534

3.  Cyclosporin. Formulation of dosage forms.

Authors:  T Cavanak; H Sucker
Journal:  Prog Allergy       Date:  1986

4.  Cyclosporine A capsules: bioavailability and clinical acceptance study in renal transplant patients.

Authors:  C Zehnder; T Beveridge; E Nüesch; A Abisch; G Thiel
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

5.  Effect of the application form of cyclosporine on blood levels: comparison of oral solution and capsules.

Authors:  B Nashan; J Bleck; K Wonigeit; P Vogt; U Christians; K F Sewing; T Beveridge; R Pichlmayr
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

6.  Simplified liquid-chromotographic analysis for cyclosporin A, and comparison with radioimmunoassay.

Authors:  S G Carruthers; D J Freeman; J C Koegler; W Howson; P A Keown; A Laupacis; C R Stiller
Journal:  Clin Chem       Date:  1983-01       Impact factor: 8.327

Review 7.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

8.  Cyclosporine metabolism and pharmacokinetics following intravenous and oral administration in the dog.

Authors:  B Gridelli; L Scanlon; R Pellicci; R LaPointe; A DeWolf; H Seltman; W Diven; B Shaw; T Starzl; A Sanghvi
Journal:  Transplantation       Date:  1986-03       Impact factor: 4.939

9.  Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism.

Authors:  W M Awni; B L Kasiske; K Heim-Duthoy; K V Rao
Journal:  Clin Pharmacol Ther       Date:  1989-01       Impact factor: 6.875

  9 in total
  1 in total

Review 1.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.